LY294002 - PI3K/BET Dual Inhibitor. CAS# 154447-36-6 6057 it displayed potent antileukemic activity

it displayed potent antileukemic activity in bone marrow blasts from AML patients regardless of FLT3 mutation status

I-BRD9 was used at 10 µM final concentration in vitro and in cellular assays

A very useful small molecule collection to improve CRISPR editing efficacy

Su-11274 exhibits a selective inhibition pattern toward different receptor mutated variants

It showed selectivity for Ral relative to the GTPases Ras and RhoA and inhibited tumour xenograft growth to a similar extent to the depletion of Ral using RNA interference

LY294002 - PI3K/BET Dual Inhibitor. CAS# 154447-36-6 6057 it displayed potent antileukemic activityLY294002, CAS No. 154447 36 6, is a potent and selective small molecule PI3K inhibitor, inhibits PI3K with IC50 of 0. 5 M, 0. 57 M and 0. 97 M, respectively. It is the most widely used PI3K inhibitor to study the role of phosphoinositide 3 kinases in the signal transduction pathways involved in cell migration, proliferation, survival, and metabolism. LY294002 inactivates Akt PKB, consequently inhibiting cell proliferation and inducing apoptosis. It is